Graphene pioneer Paragraf acquires bio-sensor startup Cardea
Graphene device manufacturer Paragraf Ltd. (Cambridge, England) is acquiring graphene biosensor pioneer Cardea Bio Inc. (San Diego, Calif.).
Paragraf’s revenue is based on graphene-based magnetic field and current sensor products while Cardea Bio pursues biocompatible sensors and test kits for healthcare, agriculture and environmental monitoring. The amount to be paid for Cardea Bio was not disclosed.
Cardea Bio becomes Paragraf USA and Michael Heltzen, former CEO and co-founder of Cardea Bio, becomes executive vice president of strategy at Paragraf USA.
The creation of Paragraf USA is a significant move towards realising Paragraf’s ambition of a world beyond silicon electronics, where graphene and other 2D materials create faster and more-efficient semiconductor devices and technologies – in short: a new frontier in electronics.
“The world-leading IP and expertise in graphene-electronic-based molecular detection using CRISPR and other bioassay methods from Cardea Bio, combined with Paragraf’s ground-breaking developments in scalable graphene production processes will deliver a strong pipeline of biosensing products aimed at solving major global challenges,” said Simon Thomas, Paragraf CEO and co-founder, in a statement.
He added: “With our existing product lines of current, position and cryogenic sensors – all built on graphene – they will advance Paragraf’s vision of Healthy People, Healthy Cities and Healthy Planet.”
Paragraf said it expects the integration of Cardea Bio to be complete by early summer.
Related links and articles:
News articles:
Paragraf opens second UK graphene electronics manufacturing site
SRC invites startup Cardea to help define bio-electronics roadmap
Paragraf raises $60 million for graphene
Graphene wafers in production at Paragraf
CEO interview: Building a graphene industry, one layer at time
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
